Work

Small Interfering Rna Therapeutics for Diabetes Complications: Mechanisms, Delivery Barriers and Clinical Prospects

Year: 2026
Type: article
Abstract: Diabetes complications remain major causes of visual loss, kidney failure, pain, and disability despite improvements in risk-factor management. Small interfering RNA (siRNA) recruits the RNA-induced silencing complex to degrade a selected messenger RNA, offering sequence-directed suppression of disease-associated genes. This review assesses evidence for siRNA in diabetic retinopathy, kidney disease, and neuropathy, alongside delivery, safety, and clinical translation. Evidence remains uneven and largely preclinical. The strongest human evidence is PF-04523655, an intravitreal siRNA against RTP801/REDD1 tested in a phase 2 diabetic macular edema trial. The highest dose showed a numerical visual-acuity advantage over laser, but the study stopped early under prespecified futility and discontinuation criteria and did not establish efficacy. Kidney candidates, including TGF-β1, Cyp4a14, and podocyte-directed HDAC4, have shown molecular or histological effects in cells or diabetic animals. Neuropathy studies targeting PTEN, IRE1α, PARP1, and long noncoding RNAs report changes in nerve regeneration, electrophysiology, pain behavior, or autonomic measures in rodents. These results do not demonstrate clinical benefit. Eight siRNA medicines had US FDA approval by November 2025, but none treats a diabetic complication. The main barrier is productive, cell-selective delivery beyond the liver. Stability, cellular uptake, endosomal escape, immune activation, off-target silencing, long-term safety, and patient-relevant trial outcomes require further study. siRNA is a promising research platform, not an established treatment for diabetic retinopathy, nephropathy, or neuropathy.
Language: English
Open Access status: green
OpenAlex ID: W7226025399
FWCI:
Cites:
Cited by:
Related to: 10